May 17, 2020

The digital pill has just been approved

Digital pill
The US Food and Drink Administration
Sophie Chapman
2 min
The US Food and Drug Administration has approved the digital pill
The US Food and Drug Administration has approved the use of a tiny censor that will monitor patient’s medication taking.

The dubbed Abilify MyCite is...

The US Food and Drug Administration has approved the use of a tiny censor that will monitor patient’s medication taking.

The dubbed Abilify MyCite is the first of its kind to be greenlighted, and is targeted at people suffering with mental health illnesses, such as schizophrenia and bipolar disorder.

Digital pills are usually the size of a grain of sand and can communicate with external devices, such as apps and patches.

The sensor is designed to tackle the expenditure of patients not taking their medication on time or at all.


In the US taxpayers are spending between $100bn and $289bn on this issue per year, due to symptoms escalating and patients ending up in hospital.

This technology aims to prevent that by tracking their medication intake through the GPS-like system.

Professionals will now be able to know a patient’s compliance with their regimen, as opposed to receiving a self-report, and therefore will be able to encourage correct intake.

Another purpose for the invention of the digital pill is the ability to perfectly tailor and personalise medicine for patients.

Due to the lack of diversity in clinical trials, medication is often given following a one-size-fits-all manner.

One of the most frequent flaws with this is women are often given larger doses than necessary because of the size of the average man the medication has been tested on being larger than the woman.

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article